IP Library Granted Patent US 9,434,784
Granted Patent B1
US 9,434,784 · App. 15/161,893 · Granted Sep 6, 2016

Nucleic acids encodng anti-C5A antibodies

Inventors: Russell P. Rother (Oklahoma City, OK); Douglas L. Sheridan (Branford, CT); Paul P. Tamburini (Kensington, CT); Yuchun Zhang (Cheshire, CT)
Assignee: Alexion Pharmaceuticals, Inc.
C07K16/18A61K2039/505C07K2317/24C07K2317/33C07K2317/51C07K2317/515C07K2317/56C07K2317/565C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,434,784
App. No.
15/161,893
Granted
Sep 6, 2016
Kind
B1
Abstract

The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.

Claims (27)

1. A nucleic acid encoding complementarity determining regions (CDRs) of a heavy chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human C5a, wherein the heavy chain variable region comprises the amino acid sequence depicted in SEQ ID NO:45.

2. A nucleic acid encoding complementarity determining regions (CDRs) of a light chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human C5a, wherein the light chain variable region comprises the amino acid sequence depicted in SEQ ID NO:42.

3. A nucleic acid encoding complementarity determining regions (CDRs) of heavy and light chain variable regions of an antibody, or antigen-binding fragments thereof, that bind to human C5a, wherein the heavy and light chain variable regions comprise the amino acid sequences depicted in SEQ ID NOs:45 and 42, respectively.

4. A nucleic acid encoding a heavy chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human C5a, wherein the heavy chain variable region comprises the amino acid sequence depicted in SEQ ID NO:45.

5. A nucleic acid encoding a light chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human C5a, wherein the light chain variable region comprising the amino acid sequence depicted in SEQ ID NO:42.

6. A nucleic acid encoding heavy and light chain variable regions of an antibody, or antigen-binding fragments thereof, that bind to human C5a, wherein the heavy and light chain variable regions comprise the amino acid sequences depicted in SEQ ID NOs:45 and 42, respectively.

7. A nucleic acid encoding a heavy chain of an antibody, or antigen-binding fragment thereof, that binds to C5a, wherein the heavy chain comprises the amino acid sequence depicted in SEQ ID NO: 49.

8. A nucleic acid encoding a light chain of an antibody, or antigen-binding fragment thereof, that binds to C5a, wherein the light chain comprises the amino acid sequence depicted in SEQ ID NO: 40.

9. A nucleic acid encoding a heavy chain and a light chain of an antibody, or antigen-binding fragment thereof, that binds to human C5a, wherein the heavy chain comprises the amino acid sequence depicted in SEQ ID NO: 49 and the light chain comprises the amino acid sequence depicted in SEQ ID NO: 40.

10. An expression vector comprising the nucleic acid according to claim 1 .

11. A cell comprising the expression vector according to claim 10 .

12. An expression vector comprising the nucleic acid according to claim 2 .

13. A cell comprising the expression vector according to claim 12 .

14. An expression vector comprising the nucleic acid according to claim 3 .

15. A cell comprising the expression vector according to claim 14 .

16. An expression vector comprising the nucleic acid according to claim 4 .

17. A cell comprising the expression vector according to claim 16 .

18. An expression vector comprising the nucleic acid according to claim 5 .

19. A cell comprising the expression vector according to claim 18 .

20. An expression vector comprising the nucleic acid according to claim 6 .

21. A cell comprising the expression vector according to claim 20 .

22. An expression vector comprising the nucleic acid according to claim 7 .

23. A cell comprising the expression vector according to claim 22 .

24. An expression vector comprising the nucleic acid according to claim 8 .

25. A cell comprising the expression vector according to claim 24 .

26. An expression vector comprising the nucleic acid according to claim 9 .

27. A cell comprising the expression vector according to claim 26 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2016
From: SHERIDAN, DOUGLAS L.; TAMBURINI, PAUL P.; ZHANG, YUCHUN
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 038727/0576 →
Continuity (6)
Division 15040258 · Feb 10, 2016
Continuation 14933368 · Nov 5, 2015
Division 14657176 · Mar 13, 2015
Division 13695277
Provisional Application 61471465 · Apr 4, 2011
Provisional Application 61330260 · Apr 30, 2010